News and Trends 25 Jan 2017
Novartis Relies on Biotech to keep up its Solid Financial Performance
Novartis has announced excellent results for 2016. Could its strong focus on biotech be the key to the big pharma’s success? Novartis just released its 2016 financial report, boasting €45.2B ($48.5B) in net sales and its therapeutic antibody for psoriasis, Cosentyx (secukinumab), becoming a blockbuster. The Swiss pharma is suffering competition from generics, but it expects […]